![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Strontium89 is an FDA-approved, non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer and is agnostic of the primary tumor.
Lead Product(s): Strontium Chloride, Sr-89
Therapeutic Area: Oncology Product Name: Metastron
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: isoSolutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 10, 2021
Details:
Under the terms of the agreement, Clionix has received exclusive rights to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait & Pakistan.
Lead Product(s): Strontium Chloride, Sr-89
Therapeutic Area: Oncology Product Name: Metastron
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clionix
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 12, 2021